Kezar Life Sciences Inc. is planning an IPO of up to $80.5 million of its ordinary shares on the Nasdaq Global Market.
The South San Francisco, Calif.-based biotechnology company, which plans to list under the trading symbol KZR, intends to use the proceeds to fund the development of its lead product candidate KZR-616 as a potential treatment of multiple autoimmune and inflammatory diseases.
Jefferies and Cowen are acting as lead book-running managers for the IPO, and Wells Fargo Securities and William Blair are acting as the joint book-running managers.
